Nektar Therapeutics Prices Public Offering of Common Stock

          Nektar Therapeutics Prices Public Offering of Common Stock

PR Newswire

SAN FRANCISCO, Jan. 22, 2014

SAN FRANCISCO, Jan. 22, 2014 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:
NKTR) ("Nektar") today announced the pricing of its previously announced
underwritten public offering of 8,500,000 shares of its common stock at a
public offering price of $12.75 per share. In connection with this offering,
Nektar has also granted to the underwriters a 30-day option to purchase up to
an additional 1,275,000 shares of common stock.

J.P. Morgan and Jefferies are acting as joint book-running managers in the
offering. William Blair, Cowen and Company, Piper Jaffray, Brean Capital and
Roth Capital Partners are acting as co-managers for the offering.

Nektar intends to use the net proceeds from this offering for general
corporate purposes including research and development funding and working

The securities described above are being offered by Nektar pursuant to an
effective shelf registration statement, including a prospectus supplement and
accompanying prospectus, copies of which may be obtained from the offices of
J.P. Morgan Securities LLC, attention Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, New York, NY 11717, or telephone: 866-803-9204
or Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue,
12th Floor, New York, NY, or telephone: 877-547-6340 or by emailing

This press release does not constitute an offer to sell, or the solicitation
of an offer to buy these securities, nor will there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.

SOURCE Nektar Therapeutics

Press spacebar to pause and continue. Press esc to stop.